Cardiology
>
Dyslipidemia
—
Clinical outcomes pending for people with elevated LDL cholesterol and triglycerides
by
Nicole Lou,
Senior Staff Writer, MedPage Today
May 28, 2024
The liver APOC3-targeted RNA interference agent plozasiran proved its triglyceride-lowering effects in people with mixed hyperlipidemia in the phase IIb MUIR trial.
In such individuals, known to be at increased risk of atherosclerotic cardiovascular disease (ASCVD), plozasiran at various doses conferred significantly larger reductions over placebo in fasting triglyceride level from baseline to week 24 — ranging from 44.2 percentage points with the 50-mg-half-yearly dose to 62.4 percentage points with the 50-mg-quarterly dose (P
Information contained on this page is provided by an independent third-party content provider. This website makes no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact editor @americanfork.business
